CORRESP Filing
Connect Biopharma Holdings Ltd
Date: June 24, 2025 · CIK: 0001835268 · Accession: 0001193125-25-145761
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-287918
Letter
Re: Connect Biopharma Holdings Limited Registration Statement on Form F-3 File No. 333-287918 To the addressee set forth above: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Connect Biopharma Holdings Limited, respectfully requests that the effective date of the Registration Statement on Form F-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on June 26, 2025, or as soon as practicable thereafter. If you have any questions or require additional information, please contact Michael E. Sullivan of Latham & Watkins LLP at (858) 523-3959. Thank you for your assistance and cooperation in this matter.
Connect Biopharma Holdings Limited 3580 Carmel Mountain Road, Suite 200 San Diego, CA 92130 June 24, 2025 VIA EDGAR Alan Campbell Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549
Sincerely,
CONNECT BIOPHARMA HOLDINGS LIMITED
Show Raw Text
CORRESP 1 filename1.htm CORRESP Connect Biopharma Holdings Limited 3580 Carmel Mountain Road, Suite 200 San Diego, CA 92130 June 24, 2025 VIA EDGAR Alan Campbell Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Connect Biopharma Holdings Limited Registration Statement on Form F-3 File No. 333-287918 To the addressee set forth above: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Connect Biopharma Holdings Limited, respectfully requests that the effective date of the Registration Statement on Form F-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on June 26, 2025, or as soon as practicable thereafter. If you have any questions or require additional information, please contact Michael E. Sullivan of Latham & Watkins LLP at (858) 523-3959. Thank you for your assistance and cooperation in this matter. Sincerely, CONNECT BIOPHARMA HOLDINGS LIMITED By: /s/ Jeff Cohn Jeff Cohn General Counsel and Corporate Secretary cc: Barry Quart, Pharm.D., Connect Biopharma Holdings Limited Michael E. Sullivan, Latham & Watkins LLP